Objective: We explored whether the opiate, morphine, affects the actions of maraviroc, as well as a recently synthesized bivalent derivative of maraviroc linked to an opioid antagonist, naltrexone, on HIV-1 entry in primary human glia.
Introduction
The predominant HIV-1 isolates from the central nervous system (CNS) preferentially use the b-chemokine HIV-1 co-receptor CCR5 (R5-tropic HIV-1 strains) to infect cells [1, 2] . m-Opioid receptor (MOR) agonists including morphine, methadone, and [D-Ala 2 , N-MePhe 4 , Glyol]-enkephalin (DAMGO) increase the expression of CCR5 and promote the replication of R5-tropic HIV-1 [3] [4] [5] , while these increases can be prevented with blockade of MOR by the inhibitors b-funaltrexamine, methylnaltrexone, and naltrexone [6] . Moreover, in addition to opioid drugs, endogenous MOR ligands, which are elevated by inflammation, neuropathic pain, and stress, can also increase HIV-1 replication [7] . The proposed interactions of CCR5 and MOR [3, 8] are thought to result from altered signaling through heterologous desensitization [9] or possibly mediated by direct molecular interactions through protein-protein dimerization/oligomerization [3, 10, 11] . Accordingly, by virtue of their ability to alter CCR5, drug abuse or maintenance therapy could alter the effectiveness of antiretroviral medications targeting CCR5 such as the HIV-1 entry inhibitor, maraviroc, which is used in combined antiretroviral therapy. Therefore, assuming CCR5 forms functional dimers/oligomers with MOR [12, 11] and opioid drugs interact with CCR5 to exacerbate HIV-1 neuropathogenesis [13, 14] , it may be advantageous to selectively target CCR5-MOR receptor complexes in opiate-abusing populations.
A novel approach to targeting these protein complexes is accomplished using newly synthesized bivalent ligands to target reputed G-protein-coupled receptor (GPCR) dimers/oligomers. Studies by others have shown that bivalent ligands can be powerful molecular tools to either characterize GPCR protein-protein interactions [15] [16] [17] [18] [19] , interfere with the function related to such interactions [20] [21] [22] , or even to treat diseases [12, 23] . Although viral production takes place mainly in brain macrophages and microglial cells, other neural cell types such as the astrocytes may harbor HIV-1 in a more dormant state, contributing to the viral burden in the brain. Numerous evidence suggests that a small subset of astrocytes becomes chronically infected, though with very limited viral production and predominant expression of nonstructural HIV-1 components [24] . Moreover, unlike macrophages, astrocytes show unique synergistic increases in CCL5 with morphine in combination with HIV-1 Tat [13, 25, 26, 14] and infected astrocytes contribute to HIV-1-associated neuropathogenesis [27] , making astrocytes important cellular targets for HIV-1.
Accordingly, we investigated the extent to which morphine affects maraviroc efficacy on HIV-1 entry; explored the potential inhibitory effects of a bivalent ligand carrying the MOR antagonist, naltrexone, and the CCR5 antagonist, maraviroc, on HIV-1 viral entry; and examined the impact of morphine on this small-molecule bivalent antagonist's to repress viral invasion in primary human glia. Our data show that actions of the novel bivalent ligand are cell-type-specific and function more effectively in astrocytes than in microglia, and linkage of the two antagonists may be more effective at blocking viral entry than the combined actions of unlinked maraviroc and naltrexone.
Methods

Reagents
Morphine sulfate was obtained from the National Institute on Drug Abuse (NIDA) and was used at a concentration of 500 nmol/l. Naltrexone (1.5 mmol/l) and maraviroc were purchased from Sigma-Aldrich (St Louis, Missouri, USA).
Construction of the m-opioid receptor and CCR5 heterodimer model
The CXCR4 chemokine receptor (Protein Data Bank, http://www.rcsb.org/pdb/home/home.do: 3ODU) was chosen as the CCR5 homology modeling template because it exhibits the highest degree of sequence identity with CCR5. MODELLER was used to generate initial CXCR4-based models of CCR5 and the model was further optimized through energy minimization and dynamic simulation. A heterodimer model of the putative CCR5-MOR interaction was then constructed based on the MOR homodimer X-ray crystal structure [28] . The CCR5 homology monomer model was overlapped over one of the monomers in the MOR dimer structure and aligned using homology-based scoring to ensure the best fit and lowest root-meansquare deviation in the helical domain (3.47 Å ).
Cell culture and treatments
Primary human glial cells (ScienCell, Carlsbad, California, USA) were cultured in 24-well plates and transfected with the plasmid pBlue3 0 LTR-luc (NIH AIDS Research & Reference Reagent Program) using Lipofectamine 2000 (Invitrogen, Grand Island, New York, USA) followed by infection with HIV-1. After 18-20 h, cells were rinsed twice in 1Â phosphate-buffered saline and then lysed in Cell Culture Lysis Reagent (Promega, Madison, Wisconsin, USA) and relative Tat protein expression was determined by measuring luciferase activity using the Luciferase Assay System (Promega; catalog # E1500). Fluorescence intensity was measured using a PHERAstar FS plate reader (BMG Labtech, Cary, North Carolina, USA). Maraviroc and the bivalent compound were initially used at increasing concentrations of 10, 50, 100, and 500 nmol/l, 30-60 min prior to HIV-1 infection to selectively block viral entry. A concentration of 100 nmol/l was chosen as both drugs showed greatest efficacy without loss in cell viability.
HIV-1 infection of glial cells
Primary human glial cells were infected by incubation with the neurotropic HIV-1 strain SF 162 originally isolated by Dr Jay A. Levy [29] . A concentration of HIV-1 p24 50 pg/10 6 cells [30] was used, and a culture lacking virus served as a negative control. Viral stocks were quantified by assaying for HIV-1 p24 (Alliance p24 Antigen ELISA Kit; Advanced Bioscience, Kensington, Maryland, USA).
Flow cytometry MOR and CCR5 immunoreactivity was detected by direct immunofluorescence with flow cytometric analysis as previously described [30] . Cells were incubated with primary MOR antibody (Novus Biologicals, LLC; Littleton, Colorado, USA; catalog number NBP1-31180) followed by a secondary antibody conjugated to allophycocyanin (BioLegend Inc., San Diego, California, USA; catalog # 408001) and Alexa Fluor 488 conjugated antimouse CD195 (CCR5) antibody (BioLegend Inc.; catalog # 107008) in permeabilization buffer at a 1 : 500 dilution. Fluorescence was measured from at least 10 000-gated cells per treatment in each experiment using a FACSCanto II flow cytometer (BD Biosciences, San Jose, California, USA).
Cytokine release
The protein levels of the cytokines tumor necrosis factora (TNF-a), interleukin-6 (IL-6), IL-1b and the chemokine RANTES were measured by ELISA at 18-20 h after treatment (R&D Systems, Minneapolis, Minnesota, USA).
Cytotoxicity assay
Live and dead cells were assessed after 24 h treatment by measuring acridine orange/propidium iodide dual fluorescence using a Cellometer Vision CBA (Nexcelom Bioscience LLC, Lawrence, Massachusetts, USA).
Statistical analysis
Data were analyzed using analysis of variance (ANOVA) techniques (SYSTAT 11.0 for Windows; SYSTAT Inc., Chicago, Illinois, USA) followed by Duncan's post hoc analyses. An alpha level of P < 0.05 was considered significant.
Results
A bivalent ligand targeting the putative m-opioid receptor-CCR5 dimer Accumulating in-vitro studies have demonstrated that CCR5 and MOR may crosstalk with each other by undergoing dimerization [9] [10] [11] 31, 32] . As shown in Fig. 1a , these two receptors may interact favorably through interfacing of transmembrane helices Vand VI to form a heterodimer. A bivalent ligand was designed and synthesized as proof-of-concept to study this putative dimerization process and its potential role in viral inhibition ( Fig. 1b) [12] . Naltexone, a MOR antagonist, has been successfully applied to investigate the dimerization of opioid receptors [33, 34] and is used clinically to treat opiate addiction and alcoholism [35, 36] . Maraviroc is the only Food and Drug Administration (FDA) approved CCR5 antagonist to treat HIV-1 infection. Both naltrexone and maraviroc show high affinity and reasonable selectivity toward MOR and CCR5, respectively.
The locus on each pharmacophore for tethering two pharmacophores through a spacer affects the bind ing affinities of the resultant bivalent ligands [37, 38] .
The consensus of several studies is that a spacer, 16-22 atoms in length, is most beneficial for targeting GPCR dimers and that a 21-atom spacer is ideal when both pharmacophores are antagonists at their respective receptors [39, 40] . The rationale for design of such spacers (containing one alkyldiamine moiety and two diglycolic units) is to keep a favorable balance between hydrophobicity and hydrophilicity, as well as to possess reasonable rigidity, high stability, and low toxicity. The chemical synthesis, binding affinity characterization, and the preliminary effects on HIV infectivity of this novel ligand have been reported recently [23, 41] .
Antiviral effect of maraviroc and the bivalent ligand in human astroglia
HIV-1 SF162 infectivity of human glia was determined based on the relative amount of Tat protein expressed by the virus using a luciferase-based reporter assay, whereas levels of tat gene expression were determined by qRT-PCR ( Supplementary Figure 1 sufficient time for viral infection. In addition, we wanted to pick a time after morphine-MOR had internalized ($17 h) and when the virus had completed a full cycle of replication ($24 h) to assess the efficacy of viral entry inhibition and the impact of morphine on the replicative capacity of the virus. After incubation with R5-tropic HIV-1 SF162 alone or in combination with morphine, relative Tat expression was significantly increased in human astrocytes (Fig. 2 ). In fact, 2.5-fold and 2.7-fold increases in Tat expression were observed after infection with HIV-1 alone and in combination with morphine, respectively. As expected, the HIV-1 entry inhibitor maraviroc prevented viral entry and caused a 2.8-fold decrease in Tat expression when compared to exposure to virus alone. By contrast, morphine in combination with maraviroc completely abolished the antiviral effect of maraviroc, and caused a significant increase in viral entry with a 2.6-fold increase in the amount of Tat expressed. Unlike maraviroc, the CCR5 antagonist TAK-779 was unaffected by morphine and limited HIV entry in both astroglia and microglia (Supplementary Figure 2 , http://links.lww.com/QAD/ A369). This unanticipated finding prompted us to ask whether the MOR antagonist naltrexone would counteract the effect of morphine on maraviroc, and indeed, Tat expression was significantly reduced ( Fig. 2a ).
We also determined whether morphine influenced the effect of the bivalent ligand on HIV-1 viral entry. Addition of the bivalent ligand was extremely effective in inhibiting viral entry in astroglia and caused a 4.4-fold decrease in Tat expression when compared to R5 HIV-1. Moreover, morphine did not influence the infection rate of virus in the presence of the bivalent compound in astroglia, which still produced a significant decrease in Tat expression that was 2.9-fold lower when compared to R5 along with maraviroc and 4.4-fold lower when compared to maraviroc with naltrexone along with morphine. Similar studies were conducted in microglia (Fig. 2b) , and although we observed an antiviral effect with maraviroc that was significantly impaired by morphine, the bivalent ligand did not prevent infectivity in microglia ( Fig. 2b) .
To further demonstrate that HIV-1 entry into astroglial cells is inhibited by the bivalent compound, we inoculated astrocytes with R5-tropic HIV-1 Bal tagged with Vpr-GFP and visualized GFP-tagged virions by confocal microscopy in the absence or presence of the bivalent ligand ( Supplementary Figure 3 , http:// links.lww.com/QAD/A369).
Expression levels of CCR5 and m-opioid receptor among human astrocytes and microglia We quantitatively measured the expression levels of CCR5 and MOR in glia by qRT-PCR. Importantly, the stoichiometric ratio of CCR5:MOR differed greatly in microglia (with higher levels of CCR5 vs. MOR), whereas CCR5 and MOR were expressed at equivalent levels in astroglia ( Supplementary Figure 4 , http:// links.lww.com/QAD/A369). The effects of maraviroc and the bivalent compound on CCR5 and MOR immunoreactivity were analyzed in virally infected glia by flow cytometry. Differences in forward scatter and side scatter intensities suggested that astroglia are heterogeneous in the expression of CCR5, with a small percentage of the total population possessing CCR5, MOR, or combined CCR5 and MOR ( Fig. 3 a,b) . The proportion of microglia possessing MOR antigenicity was even less than astroglia (Fig. 3c ). Irrespective of baseline levels of expression, the proportion of MOR þ microglia tended to remain constant regardless of treatment. Alternatively, the percentage of CCR5 þ astroglia and microglia was significantly increased after exposure to HIV-1 R5 with or without morphine ( Fig. 3a-c) , whereas exposure of infected astrocytes or microglia to maraviroc caused a significant decrease in CCR5 þ cells compared to infection alone. Interestingly, exposure to the bivalent ligand with or without morphine caused a 1.5-fold decrease in CCR5 expression levels in astrocytes compared to R5 HIV-1 alone, while increasing CCR5 þ microglia. Moreover, exposure to the bivalent ligand HIV-1 and/or drug treatments. Autofluorescence was compensated by setting the detector voltage to the minimum level that discriminates between autofluorescence and specific immunofluorescence in both negative and positive controls. Isotype control antibodies were used to define settings in histogram plot analyses. Values in each histogram indicate the mean percentages AE SEM of CCR5 and/or MOR immunopositive astrocytes (b) or microglia (c). Differences in forward scatter and side scatter intensities suggest that CCR5 and MOR are not uniformly expressed by astroglia or microglia. Moreover, co-expression (as assessed by immunofluorescence) is only present in a small proportion of astrocytes and even a smaller percentage of microglia. Importantly, unlike astrocytes, a greater proportion of microglia possessed CCR5 immunoreactivity alone, suggesting heterodimer formation only occurs in a subset of CCR5 þ microglia. Note, in the presence of virus, the proportion of CCR5 þ astrocytes decreases while CCR5 þ microglia increases following exposure to the bivalent ligand, suggesting fundamental differences in the actions of the bivalent ligand in regulating CCR5 expression in each glial type. Approximately, 20 000 events were analyzed per treatment condition in each experiment and size discrimination was used as a crude method for viability determination. caused a 1.8-fold increase in the proportion of CCR5 and MOR immunopositive astrocytes when compared to HIV-1 alone. Treatment with the bivalent ligand upregulated both CCR5 and MOR in astrocytes, but not microglia. The proportion of microglia co-expressing CCR5 and MOR was low and remained unaffected by HIV or drug exposure. Collectively, although our data show that microglia and astroglia can both express MOR and CCR5, the stoichiometric ratio of CCR5:MOR differs significantly in each cell type. Concurrent increases in the expression of CCR5 and MOR may also contribute to the selective ability of the bivalent ligand to preferentially inhibit viral entry in astrocytes.
The bivalent ligand variably affects the release of pro-inflammatory cytokines in astroglia and microglia
In an effort to determine whether viral entry inhibitors reduce the inflammatory effect associated with viral infection, HIV-1-induced pro-inflammatory cytokines were measured in HIV-1-infected astrocytes treated with maraviroc and the bivalent ligand. After 18-20 h exposure, supernatant was removed and analyzed by ELISA to quantitatively assess the release of the cytokines TNF-a, IL-1b, and IL-6 and the chemokine RANTES. Release of IL-1b was below detection levels and not reported. Exposure to HIV-1 caused significant, 1.5-fold to 3.5-fold increases in the release of TNF-a, IL-6 and RANTES compared with media alone (Fig. 4a,b) , whereas HIV-1 and morphine co-exposure significantly increased IL-6 beyond amounts seen with HIV-1 alone (Fig. 4a ). Exposure to maraviroc decreased cytokine release in HIV-1-exposed cells, whereas the combination of maraviroc with morphine in HIV-1-infected astrocytes caused a significant increase in IL-6 and RANTES (Fig. 4a) , and a significant increase in TNF-a and IL-6 in microglia (Fig. 4b) , when compared to cells treated with R5 HIV-1 and maraviroc. Likewise, exposure to the bivalent ligand with or without morphine caused a significant decrease in TNF-a, IL-6, and RANTES release in astrocytes, but had no inhibitory effect in microglia compared to HIV-1 by itself. Thus, besides inhibiting viral entry, CCR5 antagonists have variable anti-inflammatory effects in astrocytes and microglia. Interestingly, the bivalent ligand was more effective than maraviroc in inhibiting viral entry in astrocytes, although the compound was less effective at abolishing the HIV-1induced inflammation.
Effect of experimental treatments on cell viability
To determine whether HIV-1 with or without morphine exposure affected cell viability in the presence or absence of maraviroc or the bivalent compound, a cell death assay was performed 24 h after treatment. Although we observed a slight decrease in astrocytes' viability after exposure to maraviroc, it was not significantly different when compared to uninfected cells. HIV-1 AE morphine with or without maraviroc or the bivalent ligand did not significantly affect the survival of astrocytes and microglia (Fig. 5a,b ).
Discussion
The neural pathways involved in opioid enhancement of HIV-1 infection suggest possible targets for therapeutic intervention in opioid abuse-accelerated AIDS [42] [43] [44] . Furthermore, the use of drug abuse medications (e.g. methadone, buprenorphine, naloxone, and naltrexone) to prevent HIV infection [45, 46] in combination with antiretroviral medications such as efavirenz, atazanavir, and maraviroc heightens the potential for drug-drug interactions [47] [48] [49] [50] [51] . It is, therefore, important to develop new therapeutic strategies to target the consequences of opioid abuse and HIV-1 comorbidity. In this report, we observed that maraviroc inhibits HIV-1 entry into astrocytes, and coexposure with morphine negates the effects of maraviroc leading to a significant increase in viral entry. We also demonstrate that the newly synthesized bivalent ligand carrying both a MOR and CCR5 antagonist has a more potent inhibitory effect on R5-tropic viral entry in astrocytes compared to maraviroc in the presence of morphine, and the inhibitory effects of the bivalent compound were not compromised by morphine. Accordingly, the bivalent ligand might be uniquely beneficial as an adjunctive therapy with maraviroc in individuals with high levels of opiate exposure. A strategy involving bivalent ligands may be particularly advantageous for blocking possible CCR5 heterodimeric pairings that promote HIV infectivity or are beneficial in blocking CD4-independent modes of HIV entry where heterodimers substitute for CD4 in stabilizing gp41-GPCR co-receptor binding.
Possible explanations for why the bivalent ligand blocked HIV entry in astrocytes, but not microglia, include the differential affinity of maraviroc vs. the bivalent ligand for CCR5 and inherent differences in the pattern and levels of expression of CCR5, CD4, and/or MOR among astrocytes and microglia. Because the stoichiometric ratio of CCR5 and MOR expression levels is relatively equal in astrocytes vs. receptor expressions in microglia, and because the maraviroc moiety of the bivalent ligand has a lower affinity for CCR5 than unmodified maraviroc [41] , higher concentrations of bivalent ligand may be required to inhibit HIV-1 entry in microglia compared to astrocytes. In addition, the presence of CD4 on microglia, but not astrocytes, will anchor gp120/gp41, thereby increasing the likelihood of gp120/gp41-CCR5 interactions [52] . Besides CCR5, human microglia were found to express very low relative levels of MOR compared to astrocytes, suggesting there may be far fewer CCR5-MOR heterodimers available for the bivalent ligand to bind in microglia. Finally, differences in MOR splice variants expressed by astrocytes and microglia [53] (as well as underlying differences in signaling) could also contribute to this discrepancy.
Although the exact mechanism by which morphine overrides maraviroc's action is not known, it is well accepted that activation of MOR leads to upregulation of CCR5 in human host cells and facilitates HIV-1 infection and replication [5, [54] [55] [56] . These observations agree with our flow cytometry data ( Fig. 3) , in that CCR5 protein levels were significantly elevated in astrocytes after viral exposure alone or in combination with morphine. Exposure to maraviroc followed by viral infection caused a decrease in receptor levels, whereas coexposure with morphine reversed the maraviroc effect and caused an increase in CCR5 expression. The presence of morphine may increase CCR5 expression levels beyond the capacity of 100 nmol/l maraviroc to occupy CCR5 [6] . To attempt to clarify this observation, we used 500 nmol/l of [58] , the 100 nmol/l maraviroc concentration in our studies (52.9 ng/ml) is likely to approximate levels seen in CSF clinically. As with the concentration of morphine used, levels of morphine at or well exceeding 500 nmol/l are assumed to transiently occur in the CNS after heroin injection by opioid addicts [59] .
The 'dimerization-oligomerization' concept for GPCRs has been widely accepted following revealing research of several groups on metabotropic GABA B receptors [60, 61] , and further established through X-ray crystallographic modeling [62] . The dimerization/oligomerization of GPCRs poses a differentiated pharmacology from that of the monomers [63] . Thus, opiates potentially affect HIV-1 entry and infectivity via direct molecular interactions between MOR and CCR5, and/or through convergent downstream signaling [5, 10] . Accordingly, bivalent ligands have been used as tools to explore the underlying biology and pharmacology of GPCR dimerization/oligomerization, as well as to develop novel therapeutic agents to target potential disease mechanisms involving GPCR heteromeric interactions [19] .
MOR undergoes extensive alternative splicing [64] , and astrocytes express increased numbers of MOR splice variants compared to neurons and microglia [53] . We also characterized effects in astrocytes because the bivalent ligand was created based on modeling CCR5 with the canonical MOR variant MOR-1 [28] . MOR-1 is highly expressed in human astrocytes, but may not be expressed in other CNS cell types (including microglia and neurons) [53] . The concentration of 100 nmol/l was used for maraviroc and the bivalent ligand, because, as mentioned above, 500 nmol/l concentration of maraviroc showed toxicity. Thus, as the bivalent ligand requires the presence of both MOR and CCR5 for maximal binding interactions, the expression of increased numbers of MOR variants by astrocytes may require less ligand for inhibition of viral entry into this cell type. Also of importance is the affinity of the naltrexone moiety of the bivalent ligand for different MOR splice variants as well as the affinity of different MOR variants for heterodimerization with CCR5 [10] . Solving the crystal structure of human MOR [28] facilitated our ability to model the likelihood of different MOR splice variant-CCR5 combinations. Improvements in modeling are likely to lead to tailored strategies for inhibition of viral entry into specific cell types expressing a particular MOR (or CCR5 or alternative HIV-1 coreceptor) variant.
The newly synthesized ligand described herein can interact simultaneously with MOR and CCR5 receptors. Besides the novelty of this chemical property, this probe was never tested before for its potential as an antiviral drug. Interestingly, because of its specificity to the inhibition of viral entry into astrocytes, the bivalent compound may be of particular importance to decrease viral reservoirs in astrocytes, which could lead to less damage to the surrounding neurons from chronic infection. Emerging findings indicate that opiate abuse alone can increase premature Alzheimer-like neurodegenerative changes including hyperphosphorylated tau [65] . The latest evidence indicates that preferential heroin abuse exacerbates HIV-associated neurocognitive disorders [66, 67] and peripheral neuropathies [68] . Although some clinical studies report minimal or no neurocognitive differences in individuals infected with HIV who abuse opiates [69, 70] , these studies do not carefully consider critical genetic, pharmacokinetic, and pharmacodynamic differences among opiate abusers [53, 71] . Here we show that an opiate can limit the antiretroviral effects of maraviroc, whereas the coordinated blockade of MOR and CCR5, using this novel bivalent compound, has considerable potential for development as a therapeutic strategy or as a molecular tool to study HIV-GPCR coreceptor interactions.
